High-dose methylprednisolone therapy in multiple sclerosis increases serum uric acid levels

Clinical Chemistry and Laboratory Medicine

Volumn 40, Issue 5, 2002, Pages 505-508

  Toncev, Gordana ^a   Milicic, Biljana ^a   Toncev, Slavco ^a   Samardzic, Goran ^a  

^a Clinical Hospital Center   (Yugoslavia)

Author keywords

Methylprednisolone; Multiple sclerosis; Uric acid

Indexed keywords

METHYLPREDNISOLONE; PEROXYNITRITE; PURINE NUCLEOSIDE; URIC ACID;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; ENZYMATIC ASSAY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEIC ACID METABOLISM; PRIORITY JOURNAL; URIC ACID BLOOD LEVEL; ANALYTICAL EQUIPMENT; BLOOD; CASE CONTROL STUDY; STANDARD; TIME;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; REAGENT KITS, DIAGNOSTIC; REFERENCE STANDARDS; TIME FACTORS; URIC ACID;

EID: 0036293207     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2002.088     Document Type: Article

References (36)

1. Quantitative MRI changes in gadolinium-DTPA enhancement after high dose intravenous methylprednisolone treatment in multiple sclerosis
2. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect
3. Multiple sclerosis: Insights into molecular pathogenesis and therapy
4. Interactions of peroxynitrite with human plasma and its constituents: Oxidative damage and antioxidant depletion
5. Towards the physiological function of uric acid
6. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis
7. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: Implications for the treatment of multiple sclerosis
8. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
9. Magnetic resonance in multiple sclerosis
10. A rapid method for detecting oligoclonal IgG in unconcentrated CSF, by agarose isoelectric focusing, transfer to cellulose nitrate and immunoperoxidase staining
11. Rating neurologic impaitment in multiple sclerosis: An expanded disability status scale (EDSS)
12. Circadian relationship of serum uric acid and nitric oxide
13. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis
14. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
15. The pathology of multiple sclerosis and its evolution
16. Demyelination: The role of reactive oxygen and nitrogen species
17. Uric acid levels in sera from patients with multiple sclerosis
18. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood brain barrier dysfunction
19. Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxinitrite
20. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease
21. Increase in serum levels of uric acid, an endogenous antioxidant, in treatment with glatiramer acetate (GAA) for multiple sclerosis
22. Effect of corticosteroid therapy on serum and CSF malondialdehyde and antioxidant proteins in multiple sclerosis
23. Effect of methylprednisolone-pulse therapy on superoxide production of neutrophils
24. Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS
25. High-dose methylprednisolone reduces cytokine-induced adhesion molecules on human brain endothelium
26. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse
27. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury
28. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes
29. The effect of methylprednisolone on monocyte eicosanoid production in patients with multiple sclerosis
30. Monocyte-derived dendritic cells: A potential target for therapy in multiple sclerosis (MS)
31. Effects of intravenous methylprednisolone therapy on leukocyte and soluble adhesion molecule expression in MS
32. The effect of corticosteroids on serum and cerebrospinal fluid nitric oxide levels in multiple sclerosis
33. The effects of high-dose methylprednisolone on gadolinium-enhanced magnetic resonance imaging and cerebrospinal fluid measurements in multiple sclerosis
34. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in mouse model of multiple sclerosis
35. The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity
36. The role of uric acid in protection against peroxynitrite-mediated pathology